학술논문
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
Document Type
Article
Author
Pérez-García, José Manuel ; Cortés, Javier ; Ruiz-Borrego, Manuel; Colleoni, Marco; Stradella, Agostina; Bermejo, Begoña; Dalenc, Florence; Escrivá-de-Romaní, Santiago; Calvo Martínez, Lourdes; Ribelles, Nuria; Marmé, Frederik; Cortés, Alfonso; Albacar, Cinta; Gebhart, Geraldine; Prat, Aleix; Kerrou, Khaldoun; Schmid, Peter; Braga, Sofia; Di Cosimo, Serena; Gion, Maria; Antonarelli, Gabriele; Popa, Crina; Szostak, Emilia; Alcalá-López, Daniel; Gener, Petra; Rodríguez-Morató, Jose; Mina, Leonardo; Sampayo-Cordero, Miguel; Llombart-Cussac, Antonio
Source
In The Lancet 27 April-3 May 2024 403(10437):1649-1659
Subject
Language
ISSN
0140-6736